Clinical observation of disitamab vedotin combined with bevacizumab in treatment of elderly patients with refractory HER2-positive breast cancer brain metastases
Objective To observe the efficacy and safety of disitamab vedotin(DV)combined with bevacizumab(BEV)in the treatment of elderly patients with refractory human epidermal growth factor receptor 2(HER2)-positive breast cancer brain metastases(BCBM).Methods The elderly patients with HER2-positive BCBM who were admitted to Depart-ment of Oncology of Huashan Hospital Affiliated to Fudan University from November 2022 to November 2023 and had failed treatment with trastuzumab,pyrotinib,and brain radiotherapy were selected as refractory patients.They received a combined therapy of DV(2 mg/kg)and BEV(7.5 mg/kg),once every 3 weeks.The efficacy and adverse reactions were analyzed.Results Three patients met the recruited criteria.Patient 1,2 and 3 received the combined therapy as their sixth,fifth,and third line of treatment after brain metastasis,respectively.After treatment with DV 1.5 mg/kg,once every 2 weeks in patients 1 and 2,their conditions progressed.After they switched to the combined therapy,their BCBM shrank,and their progression free survival(PFS)exceeded 22 months and 11 months,respectively.In patient 3,the combined therapy was initiated direct-ly.He experienced partial remission of BCBM and his PFS was 7.5 months.All patients experienced hand and foot numbness of graded Ⅰ-Ⅱ without other significant side effects.Conclusion The combined therapy of DV and BEV has shown prelimi-nary good tolerance and response in elderly patients with refractory HER2-positive BCBM.
万方数据
维普
